

**Impact of smoking on dendritic cell phenotypes
in the airway lumen of patients with COPD**

Paul Stoll, MD¹, Ann-Sophie Heinz¹, Kai Bratke, PhD¹, Andrea Bier, MD¹,
Katharina Garbe¹, PhD, Michael Kuepper, PhD¹, J. Christian Virchow, MD¹
and Marek Lommatzsch, MD^{1§}

¹Department of Pneumology and Critical Care Medicine, University of Rostock, Germany

Additional file 1

Antigen	Label	Clone	Company
Lineage cocktail			
CD3	FITC	SK7	BD Biosciences
CD14	FITC	M \square P9	BD Biosciences
CD16	FITC	3G8	BD Biosciences
CD19	FITC	SJ25C1	BD Biosciences
CD20	FITC	L27	BD Biosciences
CD56	FITC	NCAM16.2	BD Biosciences
Other antibodies			
CD1a	PE	NA1/34	Dako
CD11c	PE	S-HCL-3	BD Biosciences
CD123	PE	9F5	BD Biosciences
Langerin	PE	DCGM4	Beckmann Coulter
HLA-DR	PerCP	L243	BD Biosciences
BDCA-1	APC	AD5-8E7	Miltenyi Biotec
BDCA-3	APC	AD5-14H12	Miltenyi Biotec
BDCA-4	APC	AD5-17F6	Miltenyi Biotec
CD11c	APC	S-HCL-3	BD Biosciences
CD80	APC	MEM-233	ImmunoTools
CD83	APC	HB15e	Invitrogen
CD86	APC	BU63	Invitrogen
CCR5	APC	2D7	BD Biosciences
MMR	APC	19.2	BD Biosciences

Table S1. Antibodies used for four-colour flow cytometry

Abbreviations denote: Blood Dendritic Cell Antigen (BDCA), Fluorescein isothiocyanate (FITC), Phycoerythrin (PE), Allophycocyanin (APC), Peridinin chlorophyll protein (PerCP), Macrophage Mannose Receptor (MMR).




Figure S1. DC surface molecules and airflow limitation in current smokers with COPD

The figure shows the correlation between the expression of CD80 (A), BDCA-1 (B), CD1a (C) and Langerin (D) on BALF mDCs (% positive mDCs in BALF) and the maximum expiratory flow when 50% of the forced vital capacity is exhaled (MEF₅₀, in % of the predicted value) in current smokers with COPD. The Spearman correlation coefficient (r) and the significance of the association (p) is given for each marker.




Fig. S2. Impact of fixed combination therapy on mDCs in BALF

Ten patients with COPD were treated with a fixed combination (+ICS/+LABA), whereas 14 patients did not receive this combination therapy (-ICS/-LABA). Boxplots show the total number of BALF cells (A), the total number of mDCs (B), the expression (% positive mDCs in BALF) of CCR5 on mDCs in BALF (C) and the concentration of the CCR5 ligand RANTES in BALF in both subgroups. Boxplots display the median (line within the box), interquartile range (edges of the box) and extremes (vertical lines). Outliers (all cases more distant than 1.5 interquartile ranges from the upper or lower quartile) were omitted in the graphs. Significant differences between two time groups are marked with the exact p-value.